Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18731290 | 0.95 | CNR1 (0.43) | CNR1CNR2HPGDSMN1; SMN2GAA | |
| SCHEMBL23680948 | 0.83 | HPGD (0.47) | HPGDSMN1; SMN2GAAKMT2AMAPK1 | |
| SCHEMBL19143407 | 0.83 | HPGD (0.47) | HPGDSMN1; SMN2GAAKMT2AMAPK1 | |
| SCHEMBL26786294 | 0.83 | HPGD (0.45) | CNR2HPGDSMN1; SMN2GAAKMT2A | |
| SCHEMBL16253038 | 0.81 | CNR2 (0.50) | CNR1CNR2ALDH1A1KDM4ERAB9A | |
| SCHEMBL16237625 | 0.80 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL3708227 | 0.80 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL16254911 | 0.78 | HSD17B10 (0.50) | HPGDSMN1; SMN2GAAKMT2AMAPK1 | |
| SCHEMBL16254936 | 0.77 | ALDH1A1 (0.51) | HPGDSMN1; SMN2GAAKMT2AMAPK1 | |
| SCHEMBL12522667 | 0.76 | NAMPT (0.45) | CNR1CNR2KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR1 2/4885CNR2 1/4885HPGD 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.